Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review

Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review

IntroductionImmune checkpoint inhibitors (ICIs) are used in several advanced malignancies and may cause various immune-related adverse events (irAEs). Among them, hematological irAEs are less described. Acquired amegakaryocytic thrombocytopenia (AAT) is a rare immune hematologic disorder characteriz...

Full description

Bibliographic Details
Main Authors: Valérian Rivet, Vincent Sibaud, Jérémie Dion, Thibaut Volosov, Mélanie Biteau, Andréa Pastissier, Karen Delavigne, Pierre Cougoul, Odile Rauzy, Thibault Comont
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
acquired megakaryocytic thrombocytopenia
immune checkpoint inhibitors (ICI)
immune-related adverse events (IRAE)
nivolumab
eltrombopag
thrombopoietin receptor agonist (TPO-RA)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1353896/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1353896/full

Similar Items